At a glance
- What the study gets you
- Access to the study treatment being tested
- Type of study
- Interventional (receives a drug or procedure)
- Time in hospital
- In-person visits at study sites — visit count not specified by the sponsor
- Drug or intervention
- RO7837195 (drug), RO7837195 Matched Placebo (drug)
- How long the study runs
- Study runs about 37 months (dates as stated)
- About the drug or intervention
- RO7837195 — drug: RO7837195 will be administered as per the schedule specified in the protocol. · RO7837195 Matched Placebo — drug: RO7837195 matched placebo will be administered as per the schedule specified in the protocol.
- Patient visit burden
- Not specified by the sponsor
- Type of study
- Testing a treatment
- Ages
- 18 Years and over
- Who
- All
- Number of participants
- 224
- Started
- 2025-09-29
- Last checked
- 2026-09
Plain English Summary
What is this study?
- • Testing a new treatment for ulcerative colitis
- • Phase2 - 224 participants
- • The purpose of this study is to evaluate the efficacy of RO7837195 compared with placebo in participants with moderately to severely active ulcerative colitis for whom prior treatment with conventional and/or advanced therapies has failed
Who can take part?
- • Ages 18 Years and over
- • Diagnosed with ulcerative colitis
Where?
- • London - Guy's Hospital
- • London - King's College Hospital
- • Liverpool - Royal Liverpool University Hospital
- • Oxford - John Radcliffe Hospital
- • +1 more UK sites
This is a simplified summary. Always discuss with your doctor before making any decisions.
About This Trial
The purpose of this study is to evaluate the efficacy of RO7837195 compared with placebo in participants with moderately to severely active ulcerative colitis for whom prior treatment with conventional and/or advanced therapies has failed.
More detail
This study consists of up to 5-week screening period, a 12-week induction phase, a 40-week active treatment extension, and a safety follow-up period following the last dose of study treatment. The induction phase will be placebo-controlled and after its completion, all participants will receive treatment with active study drug, regardless of the treatment response.
How this trial compares with your answers
Answer 2 more questions to improve match
What we know so far
Still need:
- • Tell us your age for better matching
- • Tell us your sex for better matching
Preliminary match based on your answers. Full eligibility requires on-site assessment including medical history, physical exam, and lab tests. This does not guarantee enrolment.
Eligibility at a Glance
Key info
- Age: 18 Years and over
- Who can join: All genders
What the study is looking for
- ✓Diagnosis of ulcerative colitis (UC) established at least 3 months
- ✓Moderately to severely active UC assessed by mMS
- ✓Inadequate response, loss of response, or intolerance to conventional or advanced therapies for UC
Who cannot take part
- ✗Prior extensive colonic resection, subtotal or total colectomy, or planned surgery for UC
- ✗Diagnosis of Crohn's disease or indeterminate colitis
- ✗Treatment with an advanced therapy targeted at tumor necrosis factor-like cytokine 1A (TL1a)
- ✗Inadequate response, loss of response, or intolerance to treatment of UC with an advanced therapy targeted at IL-12...
See the full criteria
Where Is This Study? (5 UK sites)
Guy's Hospital
London SE1 9RT, United Kingdom
King's College Hospital
London SE5 9RS, United Kingdom
Royal Liverpool University Hospital
Liverpool L7 8YE, United Kingdom
John Radcliffe Hospital
Oxford OX3 9DU, United Kingdom
Addenbrook'es Hospital
Cambridge CB2 0QQ, United Kingdom
How to Get in Touch
Reference Study ID Number: GA45977 https://forpatients.roche.com/ No attachments to email below.
Sponsor contactCONTACT
Fastest response: use the inquiry form. https://www.gene.com/contact-us/submit-medical-inquiry
Sponsor contactCONTACT